Protagonist Therapeutics Director Waddill Executes Stock Sale Under Pre-Arranged Plan
Protagonist Therapeutics, Inc. (NASDAQ: PTGX) director William D. Waddill has executed a significant stock sale, moving 9,000 shares of the company's common stock. The transaction, valued at $1,061,460, was carried out under a pre-arranged 10b5-1 trading plan established earlier in the year. This sale coincides with a period of elevated trading act…